Novartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meeting

13/05/2022
Novartis AG
Basel, April 11, 2022 — Novartis today announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR). Comprehensive information on the discovery of JDQ443 is also included in a poster being presented on Wednesday 13th April with further details published in the journal Cancer Discovery.